Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司
2013 Annual Results Presentation
Stock Code : 0460 Disclaimer
The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase securities, interests or assets in or of the Company. This Presentation does not constitute or contain an offer or invitation or recommendation or solicitation for the sale or purchase of securities, interests or assets in or of the Company and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any decision to purchase or subscribe for securities in any offering must be made solely on the basis of the information contained in the prospectus or offering circular issued by the company in connection with such offerings. All the information in this Presentation has been provided by the Company and has not been independently verified. No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries as to the appropriateness, accuracy, completeness or reliability of, this Presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed. And no reliance should be placed on the accuracy, fairness, completeness or correctness of the information contained in this Presentation. This Presentation is only being made available to parties who have signed and returned a confidentiality agreement and recipients are therefore bound by the confidentiality agreement in respect of all information contained herein. This Presentation is strictly private and confidential and must not be copied, reproduced, distributed or passed (directly or indirectly, in whole or in part) to any other person at any time, whether for gain or otherwise, without the prior written consent of the Company. By accepting this Presentation, the recipient has agreed to be bound by the limitations contained herein. This Presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By accepting this Presentation the recipient has agreed, upon request and at the recipient’s own costs, to return promptly all material received from the Company (including this Presentation) without retaining any copies. In furnishing this Presentation, the Company and its subsidiaries undertake no obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies therein which may become apparent, and reserve the right, without advance notice, to change the procedure for the sale of securities, interests or assets in or assets of the Company or terminate negotiations at any time prior to the signing of any binding agreement for the sale of securities, interests or assets in or of the Company. This Presentation is directed only at persons which are not “U.S. persons”( “U.S. Persons") as defined under Regulation S of the United States Securities Act of 1933, as amended and, in addition, which are lawfully able to receive this document under the laws of the jurisdictions in which they are located or other applicable laws( “relevant persons”). This document must not be acted on or relied on by persons which are not relevant persons. Any investment or investment activity to which this Presentation relates are available only to relevant persons and will be engaged in only with relevant persons. By accepting this Presentation the recipient represents and warrants that (a) it is lawfully able to receive this document under the laws of the jurisdiction in which it is located or other applicable laws; (b) it is not a U.S. Person, (c) this Presentation is furnished to it outside the United States, and (d) it will not reproduce, publish, disclose, redistribute or transmit this Presentation directly or indirectly, into the United States or to any U.S. Person either within or outside of the recipient’s organisation. The distribution of this Presentation may be restricted by law in certain jurisdictions and persons in whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdictions. Any prospective purchaser interested in purchasing securities, interests or assets in or of the Company or evaluating the Company is recommended to seek its own financial and other professional advice.
1 Agenda
Results Highlights I Business Review II Financial Review III Growth Strategy IV Q&A V
2 Section 1 Results Highlights
3 Major Achievements in 2013
1 Remarkable results with revenue and net profit up by 55.6% and 44.1% to RMB4,732.70 million and RMB1,303.01 million respectively
2 Sharp sales rebound for key products: Kelinao and Oudimei Continued strong growth of promising products: Yuanzhijiu, Yeduojia, Danshen Chuangxiongqin
3 Maintained market leadership 1st in CCV prescription market with a market share of 9.3% 4th largest pharmaceutical company in China hospital market in terms of hospital purchases
4 Granted Approval for Clinical Trials for 3 Category 1.1 innovative drugs and submitted 1 IND applications for Category 1.1 innovative drug 11 Strong R&D pipeline for first-to-market generic drugs, 17 Category 3.1 new drugs under development and 22 production license applications were filed to date
5 Completed the construction of its main production and R&D base in Tongzhou, Beijing and the upgrade of all its other production bases
4 Section 2 Business Review
5 Continuous Growth of Pharmaceutical Market
China’s Total Hospital Purchases China’s Total Hospital Purchases of (RMB Bn) CCV Drugs (RMB Bn)
Growth of CCV drugs outpaced industry growth rate
82.3 503 71.7 442
366 313 46.3 257 37.9 203 30.4 23.4
2008 2009 2010 2011 2012 2013 2008 2009 2010 2011 2012 2013
Pharmaceutical industry continues to grow on the back of the accelerated pace of urbanization, aging
population and expanded national medical insurance coverage
Consolidation in the industry is intensifying due to medical reform, tightening control of hospital medical budget, spiraling price competition and the implementation of the new GMP standard
Source: IMS
6 Leading Market Position
Top 10 Corporations in China’s Hospital market in 2013 Shares in hospital market Rank Top 10 Corporations in 2013 (%)
1 PFIZER GROUP（辉瑞） 2.43% 2 ASTRAZENECA GROUP（阿斯利康） 1.86% 3 SHANDONG QILU FTY（山东齐鲁） 1.75% 4 SIHUAN GROUP（四环医药） 1.75% 5 SANOFI GROUP（赛诺菲） 1.62% 6 BHC GROUP（拜耳医药保健） 1.54% 7 JS.YANGZIJIANG FTY（江苏 扬子江） 1.52% 8 ROCHE GROUP（罗氏） 1.51% 9 KE LUN GROUP（科伦） 1.45% 10 NOVARTIS GROUP（诺华集团） 1.26%
Top 5 players in China’s CCV market in 2013 (Market share) 9.28%
4.73% 4.66% 4.27% 3.68%
Sihuan Sanofi Pfizer Shandong Jinzhou Qilu Aohong
Source: IMS 7 Market Leading Position for Key Non-exclusive Products Sihuan’s Generic Name Sihuan Market Share by Ranking Top 5 Pharmaceutical Companies and Their Market Brand Name （Total revenue） and Percentage in 2013 Share in 2013
Ranked No.2 Sihuan 1. Qilu (山东齐鲁), 55.66% (2012: No.3) Ganglioside M1 14.84% 2. Sihuan (四环医药), 14.84% GM1 (RMB 5, 549 mil) others 3. Harbin Medical University (黑龙江哈尔滨医大), 11.80%
85.16% 4. Taiji Xinan Pharm (太极西南药业), 6.22% 5. BJ Saisheng Pharm (北京赛生), 5.90% Ranked No.3 1. BJ Taide (北京泰德), 41.02% Sihuan, 2. Hayao Biological (哈药生物), 22.24% Alprostadil Yimaining 18.64% 3. Sihuan (四环制药), 18.64% (RMB 3,979 mil) others, 4. Xian Libang Pharm (西安立邦), 8.64% 81.36% 5. Chongqing Yaoyou (重庆药友), 4.04% Salviae Ranked No.2 Sihuan Miltiorrhizae and others Danshen Ligustrazine 20.55% 1. Guizhou Baite (贵州拜特制药), 79.45% Chuanxiongqin Hydrochloride 79.45% 2. Sihuan (四环医药), 20.55% Injection (RMB2,162 mil) Ranked No.1 Sihuan 1. Sihuan (四环医药), 24.94% Cerebroprotein 24.94% 2. Yunnan Mengsheng (云南盟生), 23.14% Qu’Ao Hydrolysate 3. Shanxi Pude Pharm (山西普德), 18.94% (RMB1,576mil) others 4. GD Longfu Pharm (广东隆赋), 16.45% 75.06% 5. GD Baike (广东百科), 5.75% Ranked No.1 1. Sihuan (四环医药), 57.61% 2. Hefei Pingguang (合肥平光), 31.01% Ligustrazine Sihuan Chuanqing 3. Shandong Tianfu (山东天福), 4.01% (RMB 491 mil) 57.61% others, 4. Changchun Yuandaguoao (长春远大国奥), 3.07% 42.39% 5. Fujian Mindong Jiexun (福建闽东捷迅), 2.75% Ranked No.3 1. Jilin Boda Pharm (吉林博大), 23.68% (2012: No.4) Sihuan 2. Simcere Dongyuan (先声东元), 22.02% Edaravone others, Qingtong 3. Sihuan (四环制药), 16.85% (RMB2,738 mil) 16.85% 83.15% 4. Anhui Guorui Pharm (安徽国瑞), 16.08% 5. Kunming JIDA(昆明积大), 13.58%
8 Diversified Product Portfolio: Product Sales Contribution Breakdown in terms of Hospital Purchase Price (IMS Figure)
For the year ended 31 Dec 2013
*Promising Product (Products launched after HKEx listing in 2010) Others 2.39% *Oudimei Kelinao 18.61% 14.07% Pojia 1.38% GM1 9.36% Bi'ao 1.59%
Luoanming 3.22% *Yimaining Chuangqing 3.78% 8.43%
Anjieli 4.34% *Yuanzhijiu 7.44% Qu'ao *Yinbixin 4.47% *Yeduojia Qingtong 5.37% 5.25% 5.25%
Danshen Chuanxiongqin 5.05%
Remarks: Product with contribution less than 1% are not displayed
Source: IMS
9 More Balanced Revenue Stream Revenue of CCV Products
For the year ended For the year ended 2013 Contribution Change Product Name 31 Dec 2012 31 Dec 2013 to Sales of Year of Launch Other info
(RMB ‘000) (RMB ‘000) CCV Products
Oudimei 696,067 1,343,921 93.1% 29.8% 2010 P
Kelinao 649,636 1,115,331 71.7% 24.8% 2003
Yuanzhijiu 361,213 432,468 19.7% 9.6% 2010 P
Guhong 205,475 328,451 59.8% 7.3% 2011 P
Yeduojia 73,531 239,485 225.7% 5.3% 2010 P
GM1 217,098 219,827 1.3% 4.9% 2008
Yimaining 125,902 195,062 54.9% 4.3% 2010 P
Anjieli 123,360 170,327 38.1% 3.8% 2006
Danshen Chuanxiongqin 73,121 134,489 83.9% 3.0% 2011 P
Chuanqing 93,010 97,609 4.9% 2.2% 2003
Qu’Ao 92,485 103,555 12.0% 2.3% 2005
Qingtong 67,019 75,794 13.1% 1.7% 2008
Exclusive Products P Promising products Revenue of CCV drugs grew by 60.7% to RMB4,505 million Accounted for approximately 95.2% of the Group’s turnover in 2013
Strong growth attributable to: Rebound of sales of key products Kellinao and Oudimei Rapid growth of promising products 10 More Balanced Revenue Stream
Non-CCV Products
2013 For the year For the year Contribution Product ended 31 Dec 2012 ended 31 Dec 2013 Change to Sales of Year of Launch (RMB ‘000) (RMB ‘000) Name Non-CCV
Products
Central nervous Ren’Ao 13,675 14,616 6.9% 6.4% 2005 system drug
Bi’Ao 53,753 52,214 -2.9% 22.9% 2005 Respiratory drug Zhuo’Ao 14,436 17,674 22.4% 7.8% 2005
Metabolism drug Luoanming 58,205 72,910 25.3% 32.0% 2008
Anti-infective drug Pojia 35,542 31,065 -12.6% 13.6% 2009
Ren’Ao , Zhuo’Ao and Bi’Ao maintained stable growth in sales volume while lower tender prices led to slower growth of sales revenue Sales of Luoanming increased by 25.3% to RMB 72.9 million, thanks to its exclusive formulation
Roxatidine has been launched in 2H2013 and expanded its market by tender wins in two provinces and supplementary tender submissions in another provinces, and it entered drug reimbursement list of one province.
11 Strengthened Sales and Marketing Force
Completed integrating distribution Expediting the recovery of core products Kelinao and Oudimei: network of newly acquired companies Stepped up academic promotion and incentives to distributors
– Conducted clinical studies on Kelinao and commenced clinical studies on – Successful integration of its distribution Oudimei partnering with reputable hospitals network boosted its sales and marketing – Motivated distributors to promote the Group’s products by boosting efficiency incentives
Devised clear tender strategies for its products – Horizontal expansion to increase market coverage through provincial tender wins and supplementary tender submissions
– Vertical expansion to penetrate low-end markets through entering provincial EDL or NRCMC list
– Kelinao, Chuanqing and Yuanzhijiu entered EDL of Guangdong Province
– Yuanzhijiu entered EDL in Chongqing City
– Qudimei entered EDL of Hubei Province
– Kelinao, Chuanqing, Oudimei and Guhong entered EDL in Xinjiang Autonomous Region
– Kelinao and Oudimei entered the NRCMSL of 10 provinces respectively
12 Our Six Exclusive Products
Kelinao Oudimei Yuanzhijiu
Established exclusive product Established exclusive product Promising exclusive products at earlier For improving ischemic tissue blood For promoting metabolism of the heart, stage of development supply and protecting ischemic tissue. brain tissues, and neurons of the brain For the treatment of cardio-cerebral Set to increase penetration in 3rd and tissue regeneration process vascular diseases. th 4 tier cities Expedited expansion by provincial tender Expedited expansion by provincial Won Guangdong EDL tender wins and supplementary tender tender wins and supplementary tender submissions submissions Entered Guangdong EDL Entered Hubei EDL Won Guangdong EDL tender Entered Xingjiang EDL Entered Xingjiang EDL Entered Chongqing EDL Entered NRCMC list of 10 provinces Entered NRCMC list of 10 provinces
Yeduojia Guhong Roxatidine
Promising exclusive products at earlier Promising exclusive products at earlier Promising exclusiveexclusive productsproducts at earlier stage of development stage of development stage of developmentdevelopment For the treatment of cerebrovascular Effective in protecting gastric mucosa by SalesUsed forin 2013H1: peripheral RMB129.4 nerve injuries, mil(+560.9%) multiple problems suppressing basic gastric acid secretion Expeditedneuritis, trigeminal expansion neuralgia, by provincial sciatica, and pepsin secretion tenderradiation wins sickness, and supplementary antineoplastic- inducedtender Expanded its market by Expanded its market by submissionsvomiting, pernicious in provinces anemia, where nutritional tenders Tender wins in 17 provinces tender wereanemia delayed. Tender wins in 2 provinces and Listed in the Provincial Medicine supplementary tender submissions in Expedited expansion by provincial Catalogue in 15 provinces tender wins and supplementary tender 1 province
submissions Entered drug reimbursement list
(“DRL”) of one province
13
R&D Breakthroughs O p t i m i z e d T e m p l a t e f o r M i c r o s o f t P o w e r P o i n t 2 0 0 3 Benapenem , Imigliptin Dihydrochloride and Anaprazole Sodium granted Approval for Clinical Trials for Category 1.1 innovative drugs, and Pirotinib submitted IND applications for Category 1.1 innovative drug. To date, we have submitted a total of investigational new drug applications for 7 Category 1.1 innovative drugs and obtained Approval for 5 Clinical Trials for Category 1 innovative drugs Strong R&D pipeline for first-to-market generic drugs, 17 Category 3.1 new drugs under development and 22 production license applications were filed to date 2 drugs have been classified as The National Major Innovative Drug Projects (国家“重大新药创制”科技重大专项)
Innovative Drug Generic Drug R&D Team R&D Team Focuses on discovery and development of new chemical Focuses on first-to-market generic drugs entities as novel therapeutic agents Potential to result in intellectual property rights in Key research scientists have on average over 10 years of relation to formulation, production process, improved drug R&D experience from their tenures at multinational chemical attributes or drug delivery system pharmaceutical companies
14 R&D Breakthroughs
Project Progress Pre-clinical Registration Clinical Trials Registration Trails Application Phase I Phase II Phase III Pending
CicloMulsion* L-Phencynonate Hydroloride NeuroSTAT* Cinepazide Mesilate
Imigliptin Dihydrochloride
Benapenem *Multicenter clinical trial in collaboration with Sweden-listed Anaprazole Sodium pharmaceutical company, NeuroVive
Project Product Characteristics Medical therapeutic areas Expected time to market Benapenem Category 1.1 innovative drug Anti-infective 2017 (百纳培南) Imigliptin Dihydrochloride Category 1.1 innovative drug Metabolism 2018 (盐酸依格列汀) Anaprazole Sodium Category 1.1 innovative drug Digestive 2019 (安納拉唑鈉) Innovative L-Phencynonate Hydrochloride Category 1 innovative drug CCV 2015 Drugs (左旋盐酸苯环壬酯) Cinepazide Mesilate Category 4 Exclusive new drug CCV 2015 (甲磺酸桂哌齐特) CicloMulsion® * Category 1 New drug CCV 2016 NeuroSTAT® * Category 1 New drug CCV 2017 Levetiracetam injection Category 3.1 generic drug CNS 2014-2015 (左乙拉西坦注射液) Generic Lacosamide Category 3.1 generic drug CNS 2015 Drugs (拉克酰胺) Aprepitant Category 3.1 generic drug CNS 2015 (阿瑞吡坦) 15 Sound Progress in International Collaborations
• Collaborative projects for innovative CCV products, CicloMulsion® and NeuroSTAT® , are progressing as planned • Sihuan has exclusive license to develop, • Cooperation with our APIs market and sell the products in China Apotex production facility (Largest Canadian-owned NeuroVive pharmaceutical Pharmaceutical company) AB (Sweden based and listed company)
Text
DBLS Ltd (Korean company) • Cooperation with our APIs to-BBB production facility technologies B.V. • Completed the filing of (Netherlands-based DMF to KFDA company) • Engaged in the development of brain- targeted drug delivery technologies and products • Commenced cooperation during the year under review 16 Improved Product Quality and Productivity
Completed the construction of main production and R&D base in Tongzhou, Beijing and the upgrade of all other production bases, which are all certified under the new GMP standard and cover a total of 300,000 sqm.
Total construction time took only 1.5 years, marking industry record
Chemical Drugs Production Base API and Intermediates Production Other Production Bases in in Tongzhou District, Beijing Base in Langfang, Hebei Jilin and Liaoning
Granted “High and New Technology For active pharmaceutical ingredient Production bases included Jilin Enterprise” status (“API”) manufacturing and Sihuan, Changchun Xiangtong and pharmaceutical intermediates Benxi Hengkang plants, etc. The upgrade is completed and new GMP standard certified by the end Granted “High and New Technology Jilin Sihuan granted “High and New of 2013 Enterprise” Technology Enterprise”
Operates 6 chemical medicine New GMP standard certified in 2011 Upgrade completed by the end of production lines APIs production facility passed on-site 2013 inspection by US FDA in July 2013 New GMP standard certified
In spite of rising raw material and labor costs, the Group maintained cost efficiency in its production system through achieving economic of scale from expanded sales and improved manufacturing process management.
17 Section 3 Financial Review
18 Financial Highlights
For the year ended 31 Dec Key Income Statement Items 2013 2012 Change (RMB’000) (RMB’000) Revenue 4,732,700 3,042,531 55.6% Gross Profit 3,699,714 2,289,415 61.6% Operating Profit 1,462,082 1,047,755 39.5% Profit Attributable to Owners of the Company 1,303,012 904,402 44.1%
For the year ended 31 Dec Key Financial Ratios
2013 2012
Gross Profit Margin 78.2% 75.2% Net Profit Margin 27.5% 29.7% Basic EPS (RMB cents) 25.18 17.4% Receivable Turnover (days) 56 58 Inventory Turnover (days) 34 36
19 Remarkable Revenue Growth
Revenue (RMB million) 4.8% 4,733.0 CCV 4,800 4,400 Non-CCV 4,000 3,600 95.2% 3,042.5 3,200 2,800 2,400 2,000 1,600 1,200 Revenue by Segment 800 400 CCV: RMB4,505.0 million 0 Non-CCV: RMB228.0 million 2012 2013
For the year ended 31 December
Revenue increased by 55.6% to RMB4,733 million Sales of CCV products grew 60.7% to RMB4,505 million, mainly attributable to broadened revenue base from a further diversified product portfolio
20 Stable Profit Margin
Gross profit Gross profit margin Net profit Net profit margin (RMB million) (RMB million)
4,000 100% 1,500 100% 79.5% 1,310.0 76.5% 80% 80% 3,000 75.2% 1,000 921.5 60% 800.0 60% 2,000 33.2% 3,699.7 40% 29.7% 40% 500 26.6% 1,000 2,289.0 1,714.0 20% 20%
0 0% 0 0% 2011 2012 2013 2011 2012 2013
For the year ended 31 December
In line with revenue growth, gross profit increased by 61.6% to RMB3699.7 million
Improved gross profit margin, mainly due to an increase in the sales of higher-margin products Net profit increased by 42.2% to RMB1310.1 million
21 Distribution Costs
Distribution Costs (RMB million) 2,500 60% 2,329.5 50%
2,000 49.2% 40% 43.1% 30%
1,500 20% 1,312.3 10%
1,000 0% 2012 2013
Distribution Costs % of Revenue
For the year ended 31 December
Distribution cost to total revenue increased; mainly due to:
Increased marketing and promotion expenses Increased efforts in the academic promotion of promising products and the optimization of the distribution network
22 Capital Expenditure
(RMB million)
1400 1,164.6 1200 87.9
1000 215.4 820.2 Land use rights 800 105.5 Intangible Assets 600 185.4
400 435.9 Property, Plant & 529.2 Equipment 200
0 2012 2013
For the year ended 31 December
23 Section 4 Future Strategy
24 Future Strategy
Vision Become the most competitive Chinese pharmaceutical corporation
Continue to tap potential Enriching product resources Maintaining outstanding of strong existing product through R&D, acquisition and sales and marketing capabilities resources product collaboration
Continue to tap potential of a Build and sustain a strong Continue to enhance its young and diversified product pipeline through nationwide distribution product portfolio mainly − The established innovative and network and optimize its sales composed of exclusive generic drug development and marketing system through products platform − Step up academic promotion; − Product collaboration with adjust and optimize academic The established prestigious international companies promotion model according to product mix will continue to − Acquisitions market changes differentiate Sihuan amidst − Expand product manager team Realize long-term growth fierce market competition and enhance their momentum through innovative and sustain business growth professionalism patented drugs and first-to- in the coming five years − Continue to optimize market generic drugs that distribution network, maintain expected to be launched from high efficiency of market 2015 onwards development
25 Section 5 Appendix
26 Our History
2013 . 3 Category 1.1 innovative drugs received Clinical Trial Approval . First-to-market exclusive drug Roxatidine was launched
2012 . Collaborated with Swedish company NeuroVive AB to develop two innovative CCV drugs . Acquired remaining 40% equity interest in Xuanzhu Pharma to consolidate R&D resources . Langfang Gaobo Jingband was granted the “High and New Technology Enterprise” status
2011 . Acquired Jilin Sihuan which owns three exclusive CCV drugs . Acquired 80% interest in Changchun Xiangtong which owns GM1 injection and API manufacturing facility . Acquired Jilin Sichang which owns 4 TCM CCV products . Jilin Sihuan was granted the “High and New Technology Enterprise” status . Acqusition of Benxi Leilong, from which the company gained the ownership of Yimaining
. Listed on the Hong Kong Stock Exchange 2010 . Ranked No. 4 in the Forbes 2010 list of the most promising enterprises in the PRC and No. 1 among pharmaceutical companies . Obtained a 30-year exclusive distribution rights of Yimaining
2009 . Qingtong was launched . MSPEA invested and privatized the Company with major shareholders, which then was delisted from the SGXST . Acquired 60% interest in Xuanzhu Pharma to enhance R&D capabilities of innovative drugs . Aogan was launched 2008 . Received a 20-year patent protection in the PRC for the invention and production method of non-solvated cinepazide maleate crystal for producing Kelinao and Anjieli 2007 . Listed on the main board of the SGX-ST on 23 March 2007 . Commanded the largest share of the CCV market in China . Hainan Sihuan CVD Research became a wholly-owned subsidiary of the Group
. Kelinao received a 20-year patent protection in the PRC for the synthesis process in 2004 and was granted 2004 2006 “State Torch Programme” status by the Science and Technology Ministry of the PRC in 2006 . Beijing Sihuan became a wholly-owned subsidiary of the Group in 2006 . Received a 20-year patent protection in the PRC for the improved method for producing of Kelinao in 2006
2001 2003 . Kelinao was launched in 2003 . Chuanqing was launched in 2003
. Hainan Sihuan was founded in 2001 27 Members of Sihuan Group
Our Group
R&D Centres Production Bases Sales Company
Xuanzhu Pharma Drug Research Beijing Sihuan Jilin Sichang Hainan Sihuan Tonghua Sihuan Co., Ltd Institute Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical (Innovative drugs) (Generic drugs) Co., Ltd. Co., Ltd. Co. Ltd. Co., Ltd.
Langfang Benxi Hengkang Shenzhen Sihuan Gaobo Jingband Pharmaceutical Pharmaceutical Pharmaceutical Co, Ltd. Co., Ltd. Co.,Ltd
Changchun Jilin Sihuan Xiangtong Pharmaceutical Pharmaceutical Co., Ltd. Co., Ltd.
28 Management team Our senior management has an average of 19-years experience in the Chinese pharmaceutical industry
Proven entrepreneurial success Deep understanding of China's pharmaceutical industry Expertise in operating high growth companies Proven R&D and drug acquisition track record High standard of corporate governance Extensive clinical experience
Dr. Che Fengsheng Dr. Guo Weicheng Ms. Jia Zhongxin Mr. Choi Yiau Chong Mr. Frank Wu Co-founder, Co-founder, Chief Operating Officer Chief Financial Officer Chief Scientific Officer Executive Chairman & Executive Deputy Chief Executive Officer, Chairman Executive Director Executive Director 8 years of clinical 6 years of clinical Over 20 years of Extensive finance and 16 years of experience in the experience as a experience as a experience in accounting experience pharmaceutical industry at neurologist general surgeon operational gained from a publicly- Guilford Pharmaceuticals and management of listed company and Boehringer Ingelheim Over 19 years of Over 19 years of pharmaceutical Deloitte & Touche Pharmaceutical Inc. experience in sales and experience in sales companies in the marketing of and marketing of Member of the Extensive research project PRC pharmaceutical pharmaceutical Chartered Institute of leadership experience in products and managing products Previously CEO of a Management multidisciplinary environment pharmaceutical publicly listed Accountants (UK) and with multiple therapeutic areas
companies Chinese the Institute of Certified pharmaceutical Public Accountants of
company Singapore
29 Differentiated and proven sales and marketing model Managed and supported by our in-house dedicated sales and product managers, who ensure the efficiency, productivity and stability of our distribution network
Our Group Over 600 in-house product and sales managers
– majority of them have professional qualifications Product managers Sales managers in medicine and pharmacy
Academy marketing promotion Select and manage distributors – work with over 3,000 distributors and their sales forces to rapidly penetrate hospital Distributor Distributor Distributor • • • Distributor markets • • • We closely manage our distributors and their sales forces through: – devising marketing strategies Hospitals and physicians – organizing national and provincial conferences holding seminars in hospitals – responsible to drug biddings Patients – selecting distributors with deep knowledge and understanding of their local markets and the ones with established sales channels to local hospitals Product, marketing and promotional support; and physicians distributor selection and management – providing sales training programs for distributors Organizing and supporting medical/pharmaceutical conferences – assigning distributors to hospitals and setting sales targets – closely monitoring distributors' performance Our unique sales model has proven to be highly successful and cost-efficient, resulting in rapid and deep market penetration
30 Strong and Diversified Product Resources
Therapeutic areas CCV CNS Oncology Metabolism Anti-infective
Total Products 39 9 7 5 15
Main products Kelinao, Oudimei, Ren’ao Kaqiping Roxatidine Pojia Yuanzhijiu, Yeduojia
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Kelinao Kanglixin Ren’Ao Anjieli Anjiejian GM1 Pojia Oudimei Breviscapine Roxatidine Sodium Acetate
Chloride Hydrochloride Injection Qingtong Yuanzhijiu Chuanqing Zhuo’Ao / Bi’Ao Danshen Nalmefene Chuanxiong- Hydrochloride Yeduojia chun Qu’Ao Injection Injection
Yimaining
31 Key Products
Product Product Characteristics
Kelinao (Cinepazide Maleate Injection) (80 mg) For improving ischemic tissue blood supply and protecting ischemic tissue. Widely used in the treatments of cardiovascular and cerebrovascular and Anjieli peripheral vascular diseases. (Cinepazide Maleate Injection) (320 mg)
GM1 For neural tissue cells protection and repairing agents; for treatment of traumatic (Monosialotetrah exosylganglioside brain injuries, cerebral vascular accidents and Parkinson’s disease. sodium Injection) Widely used to treat ischemic cerebrovascular disease, coronary heart disease, Chuanqing cerebral embolism, vasculitis and vascular dementia. (Ligustrazine hydrochloride for injection) For promoting neural cell metabolism and differentiation and synthesis of brain Qu’ao protein. Widely used to treat brain cell dysfunctions caused (Cerebroprotein hydrolysate) by cerebrovascular disease, traumatic brain injuries and Alzheimer’s disease.
An oxygen free radical scavenger widely used to treat cardiovascular and Qingtong cerebrovascular diseases, as well as peripheral vascular disease (PDA) for (Edaravone Injection) people with diabetes.
32 Iconic Products
Product Product Characteristics For promoting metabolism of the heart, brain tissues, and neurons of the brain tissue Oudimei regeneration process, improving cerebral metabolic functions; clinically used for the (Cerebroside-Kinin Injection) treatment of dysfunctions caused by cardiac and brain diseases. Yuanzhijiu (Troxerutin and Cerebroprptein Hydrolysate For the treatment of cardiocerebral vascular diseases. Injection) Currently the only intravenous administration of a vitamin B compound formulation; Yeduojia used for peripheral nerve injuries, multiple neuritis, trigeminal neuralgia, sciatica, (Compound trivitamin B for Injection (II)) radiation sickness, antineoplastic-induced vomiting, pernicious anemia, nutritional anemia Danshen Chuanxiongqin injection Featuring anti-platelet aggregation, vasodilation and improving microcirculation, it can (Salviae miltiorrhizae and ligustrazine be used to treat occlusive cerebrovascular diseases such as brain dysfunction, cerebral hydrochloride injection) thrombosis, cerebral infarction; and ischemic cardiovascular diseases such as angina pectoris, myocardial infarction, etc Roxatidine is a new generation H2 receptor antagonist. With a relatively strong anti-acid effect, Roxatidine is effective in protecting gastric mucosa by suppressing basic gastric Roxatidine acid secretion and pepsin secretion, which can speed up the healing process of ulcers. (Roxatidine Acetate Hydrochloride for Injection) The medication provides a better ulcer pain alleviation effect when compared to other similar products.
Used for targeting microcirculation and protecting organs and tissue cells. Widely used Yimaining to treat chronic arteriosclerosis obliterans, unstable angina, myocardial infarction, (Alprostadil lipid emulsion injection) coronary artery bypass surgery, cerebral infarction, ischemic spinal cord injury, diabetes, peripheral neuropathy, diabetes and kidney disease.
For the treatment of cerebrovascular problems such as cerebral insufficiency, Guhong injection cerebral embolism and cerebral hemorrhage recovery period; dysfunctions caused by (Compound of aceglutamide the awareness of liver disease, neurological surgery; mental deterioration, and memory and safflower extract) impairment.
33